|
Improvement in screening and management of at-risk individuals [78,79,80,81,82] |
Many retrospective studies [203,204] |
|
Assessment of whole tumor molecular pattern [203] |
No standardization of protocols [199,203,204,234] |
|
Increasing use of artificial intelligence in statistical models [206,226] |
Lack of proper clinical trials [215] |
|
Prediction of overall survival and metastasis [211,212,213,218,219,220,221,222,223,224,225] |
Lack of multivariate models of mutation status [214] |
|
Possibility to tailor treatment according to genomic expressions [230,231] |
Inter-observer variability [8] |
|
Genetic and epigenetic profiling of scanned lesions [203] |
Automatic extraction of features still underpowered [235] |
|
Preoperative identification of benign lesions [238] |
High cost of genomic testing to validate data [236] |